Q2 Earnings Forecast for OptiNose Issued By HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for OptiNose in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.75) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $9.00 target price on the stock. The consensus estimate for OptiNose's current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for OptiNose's Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.14) EPS, FY2026 earnings at ($2.91) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at $1.01 EPS.

A number of other research firms have also weighed in on OPTN. Lake Street Capital lowered shares of OptiNose from a "buy" rating to a "hold" rating and cut their price objective for the company from $17.00 to $9.00 in a research report on Thursday, March 20th. Piper Sandler restated a "neutral" rating and issued a $9.00 target price (down from $15.00) on shares of OptiNose in a report on Friday, March 21st.

OptiNose Stock Performance

Shares of NASDAQ:OPTN remained flat at $9.60 during trading on Wednesday. The business has a 50-day simple moving average of $9.13 and a 200-day simple moving average of $7.44. The stock has a market capitalization of $97.22 million, a P/E ratio of -2.29 and a beta of -0.88. OptiNose has a one year low of $4.82 and a one year high of $20.03.

OptiNose (NASDAQ:OPTN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.27). The firm had revenue of $18.51 million for the quarter, compared to analyst estimates of $17.70 million.

Insider Activity at OptiNose

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at approximately $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 8,213 shares of company stock worth $43,643. 2.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On OptiNose

Institutional investors have recently bought and sold shares of the business. FNY Investment Advisers LLC purchased a new stake in OptiNose during the first quarter worth approximately $40,000. Virtu Financial LLC purchased a new stake in OptiNose during the first quarter worth approximately $97,000. PenderFund Capital Management Ltd. purchased a new stake in OptiNose during the first quarter worth approximately $172,000. Deltec Asset Management LLC purchased a new stake in OptiNose during the first quarter worth approximately $206,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in OptiNose during the first quarter worth approximately $558,000. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.